Choi Y-I, Hwang S, Park G-C, Namgoong J-M, Jung D-H, Song G-W, Ha T-Y, Moon D-B, Kim K-H, Ahn C-S, Lee S-G
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Transplant Proc. 2013 Oct;45(8):3057-60. doi: 10.1016/j.transproceed.2013.08.074.
Pneumocystis carinii pneumonia (PCP) is an opportunistic infection associated with morbidity and mortality in solid-organ transplant recipients. We retrospectively assessed the characteristics and outcomes of liver transplant (OLT) recipients with PCP compared with those of patients with severe non-P carinii pneumonia (non-PCP) who required intensive care with mechanical ventilation.
During the 2-year period between January 2008 and December 2009, 43 adult OLT recipients had severe pneumonia requiring mechanical ventilation; of these, 8 (19%) had PCP. During this period, routine antibiotic prophylaxis was administered for the first 6 months after OLT.
The median period from OLT to development of PCP was 9.5 months (range, 1-67); the 1-year incidence was 0.9%. The 6 and 6 to 12-month incidences of non-PCP were 4.2% and 0.3%, respectively, and those of PCP were 0.3% and 0.6%, respectively. Four of 8 patients (50%) in the PCP group had a recent history of a rejection episode. PCP was associated with a higher incidence of prior antirejection treatment. There were no significant differences between PCP and non-PCP groups in age, gender, preoperative Model for End-stage Liver Disease score, primary diagnosis, graft type, and total number of rejection episodes.
These results indicate that the risk of PCP in OLT recipients is closely related to strong immunosuppressive treatment for acute cellular rejection episodes, suggesting the importance of PCP prophylaxis in these patients. Because most patients developed PCP at around 1 year, it may be advisable to prolong routine post-OLT PCP prophylaxis for 12 months, especially among patients receiving antirejection treatment.
卡氏肺孢子虫肺炎(PCP)是实体器官移植受者中一种与发病率和死亡率相关的机会性感染。我们回顾性评估了肝移植(OLT)受者发生PCP的特征及预后,并与需要机械通气重症监护的重度非卡氏肺孢子虫肺炎(非PCP)患者进行比较。
在2008年1月至2009年12月的2年期间,43例成年OLT受者发生了需要机械通气的重症肺炎;其中8例(19%)患有PCP。在此期间,OLT术后的前6个月进行常规抗生素预防。
OLT至发生PCP的中位时间为9.5个月(范围1 - 67个月);1年发病率为0.9%。非PCP在6个月和6至12个月时的发病率分别为4.2%和0.3%,PCP在这两个时间段的发病率分别为0.3%和0.6%。PCP组8例患者中有4例(50%)近期有排斥反应发作史。PCP与既往抗排斥治疗的较高发生率相关。PCP组和非PCP组在年龄、性别、术前终末期肝病模型评分、主要诊断、移植物类型和排斥反应发作总数方面无显著差异。
这些结果表明,OLT受者发生PCP的风险与针对急性细胞排斥反应发作的强效免疫抑制治疗密切相关,提示对这些患者进行PCP预防的重要性。由于大多数患者在1年左右发生PCP,延长OLT术后PCP常规预防至12个月可能是可取的,尤其是在接受抗排斥治疗的患者中。